1. A revised biosynthetic pathway for the cofactor F420 in bacteria
- Author
-
Colin Scott, Ney B, Colin J. Jackson, Jirgis Enm, Janine N. Copp, Martin Middleditch, Mihir V. Shah, Chris Greening, James Antoney, Edward N. Baker, Nobuhiko Tokuriki, Ghader Bashiri, Stutely Sm, Brian D. Palmer, and Sreevalsan Sreebhavan
- Subjects
chemistry.chemical_classification ,0303 health sciences ,DNA ligase ,biology ,030306 microbiology ,Chemistry ,medicine.disease_cause ,biology.organism_classification ,Cofactor ,03 medical and health sciences ,Biochemistry ,13. Climate action ,biology.protein ,medicine ,Ligase activity ,Heterologous expression ,Secondary metabolism ,Phosphoenolpyruvate carboxykinase ,Escherichia coli ,Bacteria ,030304 developmental biology - Abstract
Cofactor F420plays critical roles in primary and secondary metabolism in a range of bacteria and archaea as a low-potential hydride transfer agent. It mediates a variety of important redox transformations involved in bacterial persistence, antibiotic biosynthesis, pro-drug activation and methanogenesis. However, the biosynthetic pathway for F420has not been fully eluci-dated: neither the enzyme that generates the putative intermediate 2-phospho-L-lactate, nor the function of the FMN-binding C-terminal domain of the γ-glutamyl ligase (FbiB) in bacteria are known. Here we show that the guanylyltransferases FbiD and CofC accept phosphoenolpyruvate, rather than 2-phospho-L-lactate, as their substrate, leading to the formation of the previously uncharacterized intermediate, dehydro-F420-0. The C-terminal domain of FbiB then utilizes FMNH2 to reduce dehydro-F420-0, which produces mature F420species when combined with the γ-glutamyl ligase activity of the N-terminal domain. This new insight has allowed the heterologous expression F420from a recombinant F420biosynthetic pathway inEscherichia coli.
- Published
- 2018
- Full Text
- View/download PDF